科华生物
(002022)
| 流通市值：34.30亿 | | | 总市值：34.30亿 |
| 流通股本：5.14亿 | | | 总股本：5.14亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,350,223,553.61 | 908,526,752.98 | 443,303,887.87 | 2,428,075,213.95 |
| 营业收入 | 1,350,223,553.61 | 908,526,752.98 | 443,303,887.87 | 2,428,075,213.95 |
| 二、营业总成本 | 1,476,366,060.65 | 973,445,721.39 | 482,388,247.21 | 2,535,414,687.83 |
| 营业成本 | 809,534,413.84 | 541,247,222.45 | 256,898,023.74 | 1,399,855,969.4 |
| 税金及附加 | 8,816,821.81 | 6,650,045.93 | 2,987,181.26 | 14,549,071.01 |
| 销售费用 | 264,541,013.78 | 172,891,851.32 | 95,185,872.85 | 458,472,466.77 |
| 管理费用 | 226,338,098.92 | 146,619,709.08 | 74,003,839.26 | 408,497,161.56 |
| 研发费用 | 147,599,126.1 | 93,537,807.17 | 47,231,870.73 | 241,357,853.04 |
| 财务费用 | 19,536,586.2 | 12,499,085.44 | 6,081,459.37 | 12,682,166.05 |
| 其中:利息费用 | 35,394,425.5 | 24,015,369.67 | 11,831,392.49 | 43,742,300.34 |
| 其中:利息收入 | 18,038,066.8 | 12,450,776.85 | 4,664,811.88 | 30,980,785.71 |
| 加:公允价值变动收益 | 953,315.21 | 590,817.03 | 2,751,486.18 | 1,471,746.93 |
| 加:投资收益 | 8,587,932.79 | 7,584,766.34 | 2,366,655.72 | 22,936,968.85 |
| 资产处置收益 | 2,185,685.63 | 1,723,405.4 | 566,673.46 | 5,018,213.91 |
| 资产减值损失(新) | -436,243.91 | -1,111,195.63 | 938,462.7 | -171,167,059.71 |
| 信用减值损失(新) | -15,668,028.52 | -6,054,641.88 | -1,061,254.57 | -17,355,243.94 |
| 其他收益 | 22,980,032.21 | 19,793,553.32 | 9,435,818.17 | 87,107,494.76 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -107,539,813.63 | -42,392,263.83 | -24,086,517.68 | -179,327,353.08 |
| 加:营业外收入 | 391,904.4 | 228,520.24 | 91,438.47 | 1,554,498.7 |
| 减:营业外支出 | 3,218,684.48 | 1,656,669.99 | 461,463.78 | 7,835,980.72 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -110,366,593.71 | -43,820,413.58 | -24,456,542.99 | -185,608,835.1 |
| 减:所得税费用 | -3,438,049.26 | -6,316,546.84 | -2,773,956.2 | -8,623,725.6 |
| 六、净利润 | -106,928,544.45 | -37,503,866.74 | -21,682,586.79 | -176,985,109.5 |
| 持续经营净利润 | -106,928,544.45 | -37,503,866.74 | -21,682,586.79 | -176,985,109.5 |
| 归属于母公司股东的净利润 | -122,140,657.33 | -52,464,103.69 | -28,821,454.12 | -234,014,886.4 |
| 少数股东损益 | 15,212,112.88 | 14,960,236.95 | 7,138,867.33 | 57,029,776.9 |
| (一)基本每股收益 | -0.24 | -0.1 | -0.06 | -0.46 |
| (二)稀释每股收益 | -0.24 | -0.1 | -0.06 | -0.46 |
| 八、其他综合收益 | -1,734,692.2 | -9,747,466.32 | -9,052,139.94 | 5,095,342.54 |
| 归属于母公司股东的其他综合收益 | -1,459,628.85 | -7,858,493.21 | -7,326,715.41 | 677,590.41 |
| 九、综合收益总额 | -108,663,236.65 | -47,251,333.06 | -30,734,726.73 | -171,889,766.96 |
| 归属于母公司股东的综合收益总额 | -123,600,286.18 | -60,322,596.9 | -36,148,169.53 | -233,337,295.99 |
| 归属于少数股东的综合收益总额 | 14,937,049.53 | 13,071,263.84 | 5,413,442.8 | 61,447,529.03 |
| 公告日期 | 2024-10-22 | 2024-08-30 | 2024-04-29 | 2024-03-23 |
| 审计意见(境内) | | | | 标准无保留意见 |